Steve Stiles August 26, 2014 DALLAS, TX — Daily aspirin can cut the adjusted recurrence risk by more than a third over three to four years after acute therapy for a first “unprovoked” venous thromboembolism(VTE), suggests a combined analysis of two trials comparing aspirin at 100 mg/day vs placebo in patients with recent deep vein thrombosis (DVT) or pulmonary embolism (PE)[1]. The net clinical benefit, which also considered MI, stroke, and associated bleeding, was about 37% improved with aspirin; both outcomes in adjusted analyses were strongly significant (p=0.003 and p<0.001, respectively). That doesn’t mean aspirin is better against recurrent VTE than continued treatment with vitamin-K antagonists such aswarfarin or the new oral anticoagulants (NOACs). Treatment with those agents may lower the risk by at least twice as much, notes a report on the prospectively planned INSPIRE analysis of the combined ASPIRE and WARFASA trials, published August 25, 2014 in Circulation